| Literature DB >> 29085677 |
Bismark Sarfo1, Naa Ashiley Vanderpuye2, Abigail Addison1, Peter Nyasulu3.
Abstract
BACKGROUND: Factors associated with individual patient-level management of HIV have received minimal attention in sub-Saharan Africa. This study determined the association between support services and cluster of differentiation 4 (CD4) counts among HIV patients attending ART clinic in Ghana.Entities:
Year: 2017 PMID: 29085677 PMCID: PMC5632479 DOI: 10.1155/2017/4697473
Source DB: PubMed Journal: AIDS Res Treat ISSN: 2090-1240
Participants age distribution by sex.
| Sex | Mean | Std dev |
|---|---|---|
| Male | 44.79 | 10.25 |
| Female | 38.34 | 9.78 |
Sociodemographic characteristics of participants.
| Variable | Frequency ( | Percentage |
|---|---|---|
|
| ||
| 18–30 | 34 | 17.3 |
| 31–45 | 111 | 56.4 |
| 46–65 | 50 | 25.4 |
| >65 | 2 | 1.0 |
|
| ||
| Male | 49 | 24.4 |
| Female | 152 | 75.6 |
|
| ||
| Never attended school | 25 | 12.5 |
| Primary school | 39 | 19.5 |
| Junior high school | 89 | 44.5 |
| Senior high school | 35 | 17.5 |
| Tertiary | 12 | 6.0 |
|
| ||
| Single | 38 | 21.8 |
| Married | 90 | 51.7 |
| Divorced | 15 | 8.6 |
| Cohabiting | 23 | 13.2 |
| Widowed | 8 | 4.6 |
|
| ||
| Unemployed | 29 | 15.0 |
| Self-employed | 121 | 62.7 |
| Employed for wages | 43 | 22.3 |
Characteristics of support services participants received 12 months prior to the commencement of the study.
| Support | Frequency ( | Percentage |
|---|---|---|
|
| ||
| No | 62 | 32.5 |
| Yes | 129 | 67.5 |
|
| ||
| No | 186 | 73.1 |
| Yes | 50 | 26.9 |
|
| ||
| No | 37 | 19.4 |
| Yes | 154 | 80.6 |
|
| ||
| No | 190 | 98.5 |
| Yes | 3 | 1.5 |
|
| ||
| No | 186 | 95.9 |
| Yes | 8 | 4.1 |
|
| ||
| No | 161 | 83.0 |
| Yes | 33 | 17.0 |
|
| ||
| No | 182 | 96.3 |
| Yes | 7 | 3.7 |
|
| ||
| No | 131 | 67.9 |
| Yes | 62 | 32.1 |
Antiretroviral drugs being taken by participants.
| Medication | Frequency ( | Percentage |
|---|---|---|
| 3TC, d4T, NVP | 3 | 1.6 |
| AZT | 1 | 0.5 |
| AZT, 3TC, EFV | 26 | 14.0 |
| AZT, 3TC, NVP | 17 | 9.1 |
| AZT, 3TC, TDF | 1 | 0.5 |
| AZT, TDF, NVP | 1 | 0.5 |
| EFV, 3TC, NVP | 1 | 0.5 |
| Cotrimoxazole | 9 | 4.8 |
| TDF | 4 | 2.2 |
| TDF, 3TC, EFV | 89 | 47.9 |
| TDF, 3TC, NVP | 22 | 11.8 |
| TDF, FTC, EFV | 11 | 5.9 |
| d4T, EFV, TDF | 1 | 0.5 |
3TC = Lamivudine; d4T = Stavudine; NVP = Nevirapine; AZT = Zidovudine; EFV = Efavirenz; TDF = Tenofovir.
Participants first CD4 count results before taking antiretroviral medication.
| CD4 count (cell/mm3) | Frequency ( | Percentage |
|---|---|---|
| Below 350 | 92 | 52.3 |
| 350 and above | 84 | 47.7 |
Participants most recent CD4 count results after taking antiretroviral medication for at least 6 months.
| CD4 count (cell/mm3) | Frequency ( | Percentage |
|---|---|---|
| Below 350 | 52 | 35.1 |
| 350 and above | 96 | 64.9 |
Univariate and multivariate analysis of support services participants received (12 months prior to the study), in association with their most recent CD4 count levels.
| Support | Unadjusted |
| Adjusted |
|
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
|
| ||||
| disease ( | ||||
| No | 1 (ref) | 1 (ref) | ||
| Yes |
|
|
|
|
|
| ||||
| No | 1 (ref) | |||
| Yes | 1.52 (0.66–3.51) | 0.32 | ND | NA |
|
| ||||
| No | 1 (ref) | 1 (ref) | ||
| Yes |
|
|
|
|
|
| ||||
| No | 1 (ref) | |||
| Yes | 1.07 (0.09–12.07) | 0.96 | ND | NA |
|
| ||||
| No | 1 (ref) |
| ||
| Yes |
|
|
|
|
|
| ||||
| No | 1 (ref) | |||
| Yes | 0.76 (0.31–1.85) | 0.54 | ND | NA |
|
| ||||
| No | 1 (ref) | |||
| Yes | 2.24 (0.24–20.61) | 0.48 | ND | NA |
|
| ||||
| No | 1 (ref) | |||
| Yes | 0.79 (0.38–1.67) | 0.54 | ND | NA |
ND = not determined; NA = not applicable.